Immatics NV (IMTX)

[FACT-MASTER]

Interesting info here regarding a Phase 2 trial over at PDS Biotech:

https://ih.advfn.com/stock-market/NASDAQ/pds-biotechnology-PDSB/stock-news/89544084/pds-biotech-announces-100-clinical-response-in-ce

Excerpt 1

"As previously reported, data confirm PDS0101 treatment activates HPV16-specific CD8+ T cells. This increase was not seen in patients who did not receive PDS0101. The increase in HPV16-specific T cells generated by the treatment is positively correlated with tumor cell death, suggesting cytotoxic CD8+ T cells are important mediators of antigen-specific immunity."

Remember IMTX held back the results from the IMA203 +CD8 part of the trial. Might be interesting results - also Opdivo + IMA 203 results ( BMS) held back.

IMTX trials sre still in an early phase, imo. TCR-T category still early as well, imo.

Not sure if IMTX will be presenting at the ASH. TScan is and is also in the TCR-T category with a very strategic approach, imo.

https://www.hematology.org/meetings/annual-meeting